Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Vemircopan with Midazolam, Digoxin, and Itraconazole in Healthy Adults
NCT04709081Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Midazolam, Maximum Observed Concentration (Cmax) Of Single-dose Midazolam and 7 more. Started Dec 2019; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04709081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04709081.